ESMO 2021 journaal | Niercel- en blaascarcinoom

In dit journaal nemen dr. Michiel van der Heijden en dr. Astrid van der Veldt samen met presentator Inge Diepman het belangrijkste ESMO-nieuws op het gebied van blaas- en nierkanker door.

De volgende abstracts komen aan bod:

Blaascarcinoom

1. Dose dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (dd-MVAC) or Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): results of the GETUG/AFU VESPER V05 phase III trial
2. Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
3. Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase (Ph) 2 Results From the NORSE Study
4. High- vs low-dose preoperative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)

Niercelcarcinoom

1. Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: a randomized phase II trial (PRISM)
2. STAR. A Randomised Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the treatment of locally advanced and/or metastatic Renal Cancer (RCC)
3. Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564

Bekijk hier het volledige overzicht van onze ESMO 2021 journaals en interviews.